Feb 25 (Reuters) – Danish drugmaker Novo Nordisk has partnered with U.S.-based Vivtex Corp in a deal worth up to $2.1 billion to develop next-generation oral drugs for obesity and diabetes, the companies said on Wednesday.
Under the partnership, the privately held company will license some of its oral drug-delivery technology, while Novo Nordisk will take charge of global development and commercialization.
Here are some details:
(Reporting by Kamal Choudhury in Bengaluru; Editing by Leroy Leo)
